

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

June 24, 2025

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Press Release

Please find enclosed the press release titled **“Biocon Biologics Collaborates with National Cancer Society Malaysia, Rolls Out Patient Assistance Program to Expand Affordable Access to Biosimilars”**

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh Nand

Company Secretary

Membership No. ACS 13669

Encl: as above

PRESS RELEASE

Biocon Biologics Collaborates with National Cancer Society Malaysia Rolls Out Patient Assistance Program to Expand Affordable Access to Biosimilars

Bengaluru, Karnataka, India and Johor, Malaysia: June 24, 2025

Biocon Biologics Limited, a fully integrated global biosimilars company, has partnered with the **National Cancer Society of Malaysia (NCSM)**, a prominent not-for-profit cancer organization, to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia.

Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia.

The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints.

The MoU was signed during the National Cancer Congress Malaysia 2025 event, emphasizing a commitment to improving patient-centric healthcare.

Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics, said, *“Our partnership with the National Cancer Society of Malaysia marks a meaningful step forward in expanding access to high-quality oncology biosimilars for cancer patients in need. This collaboration, which combines our scientific expertise with NCSM’s strong community outreach and patient support network, aims to ease the treatment burden for underserved populations. Together, we hope to positively impact thousands of lives and strengthen Malaysia’s efforts to deliver inclusive, patient-centric healthcare.”*

Biocon Biologics aims to build on its previous success in expanding access to diabetes care in Malaysia, having served over 345,000 patients, and is now focusing on oncology through strategic partnerships like this.

Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics, and **Dato' Dr. Saunthari Somasundaram, President of NCSM**, signed the MoU, on the sidelines of the National Cancer Congress Malaysia 2025, held in June in Kuala Lumpur, in the presence of **Datuk Seri Dr Dzulkefly Ahmad, Minister of Health, Malaysia**.

NCSM is Malaysia’s first not-for-profit cancer organization providing education, care, and support services. It has earned a strong reputation for fair practices and community trust, making it an ideal partner for Biocon Biologics’ PAP initiative in Malaysia.

About Biocon Biologics Limited:

Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its 'lab to market' capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.

Biocon Biologics has commercialized nine biosimilars from its portfolio which are addressing patients' needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). **Website:** www.bioconbiologics.com; **Follow us on X (formerly Twitter):** @BioconBiologics and **LinkedIn:** [Biocon Biologics](#) for company updates. For FY24 Integrated Annual Report of Biocon Biologics [click here](#)

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

Website: www.biocon.com; Follow-us on X (formerly Twitter) [@bioconlimited](#) and **LinkedIn:** [Biocon](#) for company updates.

For More Information:	
MEDIA: Biocon Biologics	INVESTORS :Biocon
Seema Ahuja Global Head of Corporate Brand & Head of Communications – Emerging Markets +91 99723 17792 seema.ahuja@biocon.com	Saurabh Paliwal Head - Investor Relations +91 95383 80801 saurabh.paliwal@biocon.com